Skip to main content
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Phage therapy for multidrug-resistant infections?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Phage therapy for multidrug-resistant infections?
Gastroenterology

Phage therapy for multidrug-resistant infections?

Bacteriophages
Oncology Gastroenterology General Medicine

With the emergence of antibiotic resistance, bacteriophages are making a grand comeback. These viruses from the intestinal microbiota could eventually be used to provide more targeted treatment for multidrug-resistant infections, to give just one example. An article in Nature Reviews Gastroenterology & Hepatology looks at the history, future, and challenges of phage therapy.

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

About this article

Created 21 February 2022
Updated 23 February 2022

Bacteriophages, or simply “phages,” are the most abundant and varied biological agent on Earth. The natural predators of bacteria, they are ubiquitous in the earth, oceans... and the human intestinal microbiota, where they are the dominant type of virus. Intestinal bacterial dysbiosis, which is associated with gastrointestinal disorders such as Crohn's disease and Irritable Bowel Syndrome, goes hand in hand with compositional changes in the virome.

A century on, and they’re back in the spotlight

In the 1920s, experiments to assess the therapeutic potential of phages gave promising results in patients with shigellosis, dysentery, and cholera. This (sidenote: Summers WC. The strange history of phage therapy. Bacteriophage. 2012 Apr 1;2(2):130-133. ) was then cast aside with the arrival of antibiotics in the 1940s. Although a few studies, unfortunately badly documented ones, continued in Soviet countries, phages were relegated to the second division. However, recent concerns over multidrug-resistant infections, and a new understanding of how antibiotics impact the balance of the intestinal microbiota, have prompted a renewed scientific interest in phage therapy. Each species of phage usually targets a single species of bacteria, which means these viruses can provide a “precision” solution where broad-spectrum antibiotics fall short. Nevertheless, despite its great promise, the health care authorities have yet to authorize any phage-based therapy (except in very exceptional cases).

Antibiotic resistance, dysbiosis, targeted therapy: multiple potential uses 

(sidenote: Schooley RT, Biswas B, Gill JJ, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrob Agents Chemother. 2017 Sep 22;61(10):e00954-17.  ) attracted attention: a 68-year-old diabetic patient with pancreatitis complicated by a multidrug-resistant Acinetobacter baumannii infection regained full health in just five months thanks to phage therapy, after several failed attempts with antibiotics. Similar success stories have been reported with (sidenote: Jennes S, Merabishvili M, Soentjens P, et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury-a case report. Crit Care. 2017 Jun 4;21(1):129.  ) and (sidenote: Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019 May;25(5):730-733. ) , offering hope of a promising alternative for the treatment of multidrug-resistant bacterial infections. Phage therapy as a modulator of the intestinal microbiota is also of interest to scientists. A study in mice found that treatment with phages specific to Enterococcus faecalis, a bacterium associated with a poor prognosis in alcohol-related hepatitis, can improve the disease.

Other potential uses of phages are now being discussed, especially for precision medicine. These phages can transport potent cancer drugs and antibiotics to a precise area of the body, making it possible to increase the dose and reduce the toxicity of the treatment for adjacent tissues.

Seeking to overcome the challenges of clinical use 

Research now needs to look at ways to overcome the many questions posed by clinical practice. Is phage therapy always safe? Can it replace antibiotic treatment? What is the best method of administration and the right dose? What is their long-term effect on the microbiota and health in general? According to the authors, randomized, double-blind, placebo-controlled clinical trials are needed to legitimize the role of phage therapy, an age-old practice that could help overcome several of the challenges facing medicine today.

Sources

Duan Y, Young R, Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat Rev Gastroenterol Hepatol. 2022 Feb;19(2):135-144. 

Tags
Bacteriophage Antibiotic resistance Virus

en_view en_sources

    Created 21 February 2022
    Updated 23 February 2022

    About this article

    To know more about this topic.

    Main topic

    Bacteriophages

    Medical practice

    Oncology Gastroenterology General Medicine

    Content type

    News
    Gastroenterology

    The blue poop challenge: a reliable method to evaluate gut transit?

    By Pr. Gianluca Ianiro Gastroenterology Department, Fondazione Policlinico Universitario Agostino Gemelli- ...

    Find out more

    New perspectives in autism: the role of microbiota in social communication

    Overview By Dr. Vincent Trebossen Child and Adolescent P...

    Find out more

    Gut microbiota #15

    By Pr. Markku Voutilainen Turku University Faculty of Medicine; Turku University Hospital, Department of Ga...

    Find out more

    Microbiome topics at gastro 2021

    Congress Review By Pr. Eamonn M M Quigley Lynda K and David M Underwood Center for Digestive Disorders, Di...

    Find out more

    Commensal clostridiales strains mediate effective anti-cancer immune response against solid tumours

    Commented articles - Adults' section By Pr. Harry Sokol ...

    Find out more

    Microbiota in covid-19 pandemic

    Overview By Pr. Conceição Calhau NOVA Medical School, New University of Lisbon, Portugal By Pr. Pedro Povo...

    Find out more

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial porti...

    Find out more

    From diarrhea to chronic diseases: the well-documented consequences of antibiotic-related gut microbiota dysbiosis

    Antibiotic treatment may sometimes take place without any...

    Find out more

    Continue reading

    News
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    26.04.2022

    Severe obesity: the vicious circle of biotin metabolism

    Read the article
    22.04.2022

    SCFAs: new intestinal markers of Parkinson’s disease?

    Read the article
    15.04.2022

    Multiple sclerosis and microbiota: does meat consumption play a role?

    Read the article
    08.04.2022

    Inflammatory Bowel Disease (IBD): do microplastics condition severity?

    Read the article
    04.04.2022

    The microbiota, a significant factor in smoking cessation

    Read the article
    30.04.2019

    The lingual microbiota, biomarker of pancreatic cancer?

    Read the article
    15.06.2021

    Autism: link between severity of the disorder and changes in the gut microbiota?

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    12.05.2022

    Gonorrhea in women: a link between vaginal microbiota and symptoms?

    Read the article
    Photo: Neonatal sepsis: the microbiota pays a heavy price for antibiotic use
    09.05.2022

    Neonatal sepsis: the microbiota pays a heavy price for antibiotic use

    Read the article
    04.05.2022

    Miscarriage: Is vaginal dysbiosis a suspect?

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo